Pediatric psoriasis accounts for approximately 2% of dermatological conditions in children under 16 years of age. The objective of this study is to describe the clinical characteristics, treatment regimens, and observed efficacy and safety profiles in a real-world cohort. This retrospective study analyzed 15 pediatric patients treated with biologics in Argentina between 2010 and 2024. The median age at treatment initiation was 8 years, with a predominance of female patients. The biologics used were primarily adalimumab, followed by secukinumab, etanercept, and ixekizumab. Five patients experienced treatment failure secondary to adalimumab. The therapy was well tolerated, with no adverse events reported.The data suggest that early intervention can alter the course of the disease and prevent long-term complications.
